Our studies in lung adenocarcinoma suggest that SGLT2 is expressed in the earliest stages of cancer development, and pre-malignant lesions are exquisitely sensitive to SGLT2is because they do not express glucose transporters of the GLUT family. Here, SLC5A2 is linked to cancer.